Kevin Webster

Company: Frontier Medicines

Job title: Chief Scientific Officer

Seminars:

Taking a Direct Approach: FMC-376, a Direct Inhibitor of ON+OFF KRAS G12C, Overcomes the Primary Drivers of Both Innate & Acquired Resistance 12:45 pm

• Discovery of FMC-376 and demonstration of ON + OFF dual acting MOA • Demonstration of broad activity across PDX models representing diverse clinical resistance mechanisms • Demonstration of CNS activity and combination efficacyRead more

day: Day One Track B AM

Panel Discussion: Does Pan-RAS Hold the Future of Precision Medicine? Exploring Combination Potential & Targeting Novel Isoforms 9:30 am

• What is the scope for pan-RAS beyond canonical RAS isoforms? • What is the scope for targeting patient populations with NRAS isoforms? Can go as far as drugging melanoma? • What combination therapies should be deployed with pan-RAS and how can we inform this? Read more

day: Day One